Brexit: Regulatory accountability, batch releases, safety governance and vendor disruptions – Brexit impacts a line of critical functions for drug developing companies.
In light of the challenges facing the pharmaceutical industry NDA has developed a set of services to support the Brexit transition process. These services start with a strategic Brexit pipeline review to help our clients analyse and define the specific impact of Brexit on their products and processes.
Following the review our operational capabilities stand ready to support the implementation of the resulting transition strategy to ensure predictability and a smooth process.
Click here to learn more about how the NDA team can support you to ensure that your company is ‘BREXIT-ready’.